Home/ News & Events

New ESID Juniors Clinical Session is coming!

Topic: SAMD9L - associated inflammatory disease

Date: 14/12/2022

Time: 18:00h (CET)

Riccardo Papa (Genova, IT)

Carlos Andres Arango Franco (Paris, FR)

Click here to join the session

The Voting for the Destination of ESID Biennial Meeting 2026 is OPEN!

We are pleased to inform you that the voting for the destination of the ESID Biennial Meeting 2026 is now open and you can cast your vote online!

In memoriam of Oksana Leontieva

It is with great sadness that we learned of the tragic and death of our colleague, Oksana Leontieva, a pediatric hematologist from Ukraine and a victim of a recent missile strike in Kyiv ( 

We at ESID offer our deepest condolences to her family, friends and colleagues of the National Pediatric Ohmatdyt Hospital. 

We take this somber moment to send our thoughts and prayers in the memory of all other fellow humans who needlessly perished as a result of the current war.

Call for observations - COPA syndrome

COPA syndrome is a recently defined type I interferonopathy caused by heterozygous mutations in the gene COPA, encoding coatomer protein subunit alpha that is involved in intra-cellular transport of cargo proteins1. Although the pathogenesis is not fully understood, mutations in COPA were shown to cause an accumulation of STING at the Golgi2 where it is activated and leads to constitutive type I interferon signalling i.e. the core feature of type I interferonopathies.

Call for participation: Malignancies in IEI – an ESID registry study

ESID registry Working Party is inviting the ESID registry participants to take part in the "Malignancies in IEI" study latest by August 31st 2022.

"Call for participation" IDDA2.1 score - an ESID registry prospective study

The IDDA score has already been available as optional module (tab) in the level 1 for your own use at the initial and follow up patient entries and is designed for all IEI with immune dysregulation. Now, I am inviting your active contribution to a prospective study until end of 2023 (prolongation possible), aiming to implement a powerful tool for assessment and monitoring of disease activity and phenotype patterns!

ESID COVID-19 Statement, March 2022

Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been rapid progress with understanding disease, clinical phenotypes and biology, improving treatment and implementing vaccination trials. Data is accumulating about the impact of COVID-19 for patients with Inborn Errors of Immunity (IEI). The purpose of this statement is to summarise our state of knowledge and set out ESID’s current guidance for professionals in the IEI community in Europe. We will update this statement as evidence emerges.

ESID Position Statement

ESID Position Statement

Joint statement of solidarity and support

ESID is profoundly concerned about the grave repercussions of the conflict in Ukraine on PID community, healthcare and patients. 

Together with IPOPI, INGID and J Project stakeholders, we have released a statement of solidarity and support to those impacted by the war in Ukraine.

Hyper IgM Grant opportunity

ESID is pleased to announce an excellent grant funding opportunity